Relationship of adiponectin to serum paraoxonase 1

Atherosclerosis

Volumn 197, Issue 1, 2008, Pages 363-367

  Bajnok, Laszlo ^a,b   Csongradi, Eva ^b   Seres, Ildiko ^b   Varga, Zsuzsa ^b   Jeges, Sara ^a   Peti, Attila ^a   Karanyi, Zsolt ^b   Juhasz, Attila ^b   Mezosi, Emese ^a,b   Nagy, Endre V ^b   Paragh, Gyorgy ^b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Adiponectin; Lipid peroxidation; Obesity; Serum paraoxonase 1

Indexed keywords

ADIPONECTIN; ARYLDIALKYLPHOSPHATASE 1; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID PEROXIDATION; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADIPONECTIN; ADULT; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OVERWEIGHT;

EID: 39649103652     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.06.001     Document Type: Article

References (26)

1. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
2. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
3. Yamamoto Y., Hirose H., Saito I., et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci 103 (2002) 137-142
4. Matsubara M., Maruoka S., and Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147 (2002) 173-180
5. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
6. Yang W.S., Lee W.J., Funahashi T., et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86 (2001) 3815-3819
7. Tschritter O., Fritsche A., Thamer C., et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52 (2003) 239-243
8. Matsubara M., Maruoka S., and Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87 (2002) 2764-2769
9. Cnop M., Havel P.J., Utzschneider K.M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
10. Mantzoros C.S., Li T., Manson J.E., Meigs J.B., and Hu F.B. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 4542-4548
11. Kubota N., Terauchi Y., Yamauchi T., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (2002) 25863-25866
12. Matsuda M., Shimomura I., Sata M., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277 (2002) 37487-37491
13. Getz G.S., and Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 15 (2004) 261-267
14. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
15. Aviram M., Rosenblat M., Bisgaier C.L., et al. Paraoxonase inhibits high density lipoprotein oxidation and preserves its function: a possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
16. Rosenblat M., Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 281 (2006) 7657-7665
17. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15 (1995) 1812-1818
18. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
19. Paragh G., Asztalos L., Seres I., et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 83 (1999) 126-131
20. Seres I., Paragh G., Deschene E., Fulop Jr. T., and Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 39 (2004) 59-66
21. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
22. Sugiuchi H., Uji Y., Okabe H., et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 41 (1995) 717-723
23. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
24. Smolen A., Eckerson H.W., Gan K.N., Hailat N., and La Du B.N. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 19 (1991) 107-112
25. Galli F., Varga Z., Balla J., et al. Vitamin E lipid profile, and peroxidation in hemodialysis patients. Kidney Int 59 Suppl. 78 (2001) 148-154
26. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904